In the case of EGCG, an increase in the sensitivity to cisplatin was observed in ovarian cancer cells [38] and administered with taxanes, which contributed to inhibiting the growth of prostate tumor cells favoring their apoptosis through increasing p53, among other proteins [39], among other antineoplastics such as capecitabine [37], 5-fluorouracil, and doxorubicin [40]. The gene discussed is TP53; the disease is ovarian carcinoma.